Validation and Evaluation of a Newly Developed Mobile Diet App

Conditions:   Chronic Kidney Diseases;   Chronic Kidney Disease stage3;   Chronic Kidney Disease stage4;   Chronic Kidney Disease Stage 5;   Chronic Kidney Disease Requiring Chronic Dialysis Interventions:   Other: Counseling;   Other: Renal Diet App;   Other: Printed Nutrition Pamphlet Sponsor:   Universiti Putra Malaysia Not yet recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

CONCLUSIONS: The HRQOL of hemodialysis patients with CKD-FS remains poor, interacting with important functions such as sleep, vitality, cognition, and sexual function. PMID: 32468308 [PubMed - in process]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
In this study, simultaneous removal assessment of marker molecules from three uremic toxin groups was performed during different hemodialysis treatment modalities using optical characteristics of spent dialysate. Results from optical measurements were compared with the results from chemical laboratory. Ten chronic dialysis patients, mean age 59 ± 15 years, were included in the study during 40 hemodialysis sessions. Low-flux hemodialysis (HD), high-flux hemodialysis (HF), and postdilutional online hemodiafiltration (HDF) with different settings were used. The reduction ratio (RR) and total removed solut...
Source: ASAIO Journal - Category: Medical Devices Tags: Renal/Extracorporeal Blood Treatment Source Type: research
Conclusions: Serum sST2 is a novel biomarker associated with adverse clinical outcomes in MHD patients. It was significant for both all-cause and cardiovascular mortality in MHD patients and may provide better prognostic value in short-term prognosis than the classic biomarker NT-proBNP. PMID: 32460670 [PubMed - in process]
Source: Renal Failure - Category: Urology & Nephrology Tags: Ren Fail Source Type: research
Authors: Albalate M, Arribas P, Torres E, Cintra M, Alcázar R, Puerta M, Ortega M, Procaccini F, Martin J, Jiménez E, Fernandez I, de Sequera P, Grupo de Enfermería HUIL, Grupo enfermería HUIL Abstract Dialysis patients are a risk group for SARS-CoV-2 infection and possibly further complications, but we have little information. The aim of this paper is to describe the experience of the first month of the SARS-CoV-2 pandemic in a hospital haemodialysis (HD) unit serving the district of Madrid with the second highest incidence of COVID-19 (almost 1,000 patients in 100,000h). In the form of...
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - Category: Urology & Nephrology Tags: Nefrologia Source Type: research
Condition:   Renal Anemia Intervention:   Drug: Roxadustat Sponsor:   Astellas Pharma Inc Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: Available online 28 May 2020Source: American Journal of Kidney DiseasesAuthor(s): Shilpanjali Jesudason, Alyssa Fitzpatrick, Aarti Gulyani, Christopher E. Davies, Erandi Hewawasam, Philip A. Clayton, Stephen P. McDonald
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Condition:   Renal Anemia Intervention:   Drug: Roxadustat Sponsor:   Astellas Pharma Inc Not yet recruiting
Source: - Category: Research Source Type: clinical trials
CONCLUSION Higher doses of phenylephrine were an independent predictor of DGF. With the exception of phenylephrine, the selection and dose of vasopressor during donor management did not predict the development of DGF. LEVEL OF EVIDENCE Prognostic study, Level III.
Source: The Journal of Trauma: Injury, Infection, and Critical Care - Category: Orthopaedics Tags: ORIGINAL ARTICLES Source Type: research
This study aimed to quantify the inflammatory burden that periodontitis causes in dialysis patients. Is one modality of dialysis associated with a lower periodontal inflamed surface area?BMC Oral Health
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dental & Oral Health Journal Article Source Type: news
Purpose of review Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are orally active small molecules and are launched as novel therapeutic agents for anemia in chronic kidney disease (CKD). In contrast to conventional exogenous erythropoietin (EPO) administration, HIF-PHIs stimulate endogenous EPO production and improve iron metabolism via stabilization of hypoxia-inducible factor (HIF). This review summarizes the mechanism of action, the results of clinical trials, and future perspectives of HIF-PHIs. Recent findings Six HIF-PHIs are currently under phase III studies, some of which have been already ...
Source: Current Opinion in Nephrology and Hypertension - Category: Urology & Nephrology Tags: RENAL PATHOPHYSIOLOGY: Edited by Orson W. Moe and Susan E. Quaggin Source Type: research
More News: Dialysis | Diets | Malaysia Health | Nutrition | Research | Urology & Nephrology